Search Results for: Efficacia e sicurezza dei farmaci GLP-1 per il diabete di tipo 2 e l’obesità

Limitate alterazioni metaboliche indotte da farmaci psichiatrici

Compared with DPP-4i, SGLT2i reduced the composite pulmonary endpoint overall, prevented COPD hospitalizations primarily in fit or mildly frail patients, and conferred protection against pneumonia admissions across most frailty strata, while showing comparable benefits to GLP-1 RA. These findings suggest that both SGLT2i and GLP-1 RA may be preferred options for T2D patients with COPD, with effectiveness influenced by frailty status.

Per l’uso innovativo dell’IA nella scoperta di farmaci e vaccini

A Bergamo tornano presto ad accendersi i riflettori sulla Sanità che cambia pelle tra bisogni di salute sempre più impellenti e una governance da rivedere per gestire la spinta di…

Farmaci e vaccini sono al primo posto in Italia per surplus con l’estero, con oltre 21 miliardi di attivo nel 2024, mentre i nuovi record di produzione (56 miliardi) ed…

In Olanda è già adottato per guidare la prescrizione dei farmaci e anche in Italia cresce l’interesse per la farmacogenetica, che può prevenire effetti collaterali e fallimenti terapeutici

In JAMA Internal Medicine, Luchsinger et al describe the results of a prespecified secondary analysis of the GRADE clinical trial on cognitive performance. The GRADE trial randomized 3721 patients with type 2 diabetes using metformin at baseline to add either a long-acting insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) agonist, or a dipeptidyl peptidase-4 inhibitor. At 4 years following randomization, cognitive performance was not different between treatment groups across 3 validated cognitive tests. However, worsened glycemic control was associated with modestly lower cognitive test scores. These findings provide important data for clinicians, particularly in light of recent lay press and scientific enthusiasm about GLP-1 agonists for dementia prevention.

The US Food and Drug Administration (FDA) recently accepted a new drug application for oral semaglutide. If approved, it would be the first oral glucagon-like peptide-1 (GLP-1) receptor agonist authorized for long-term weight management. The 25-mg semaglutide pill would be marketed as Wegovy, the same name used for Novo Nordisk’s FDA-approved 2.4-mg semaglutide injection.

Positività 0,97% e 2,8%, ma va confermata. Verso test nazionale

Positività 0,97% e 2,8%, ma va confermata. Verso test nazionale

GLP-1 agonists were linked to greater risk for neovascular age-related macular degeneration.

Cellule cancerose modificano loro struttura per sfuggire farmaci

Voci di pazienti ed esperti per raccontare difficoltà e stigma